Karen S. Anderson
Yale University
122 Papers
1.1K Citations
Karen S. Anderson is an academic researcher from Yale University. The author has contributed to research in topics: Reverse transcriptase & Chemistry. The author has an hindex of 35, co-authored 122 publications. Previous affiliations of Karen S. Anderson include Yale Cancer Center & Ohio State University.
Chat about Author
Papers
Discovery of Wild-Type and Y181C Mutant Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors Using Virtual Screening with Multiple Protein Structures
Sara E. Nichols,Robert A. Domaoal,Vinay V. Thakur,Julian Tirado-Rives,Karen S. Anderson,William L. Jorgensen +5 more
TL;DR: To discover non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) that are effective against both wild-type (WT) virus and variants that encode the clinically troublesome Tyr181Cys (Y181C) RT mutation, virtual screening by docking was carried out using three RT structures and more than 2 million commercially available compounds.
Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ
Christal D. Sohl,Michal R. Szymanski,Andrea C. Mislak,Christie K. Shumate,Sheida Amiralaei,Raymond F. Schinazi,Raymond F. Schinazi,Karen S. Anderson,Y. Whitney Yin +8 more
TL;DR: For the first time, this work illuminates the mechanism of (-)-FTC-TP differential selectivity and provides a structural scaffold for development of novel NRTIs with lower toxicity.
41
Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases.
TL;DR: In vitro data confirm the mechanistic basis of KP-1212 as a viral mutagen but suggest that there may be a potential for toxicity to the mitochondria.
37
Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral Agent
TL;DR: A novel use of a guanosine prodrug approach to stabilize the nucleoside yielding the prodrug, cyclo-D4G, which possessed anti-HIV activity and had increased stability, lipophilicity, and solubility, as well as decreased toxicity relative to D4G.
37
Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers
Won-Gil Lee,Kathleen M. Frey,Ricardo Gallardo-Macias,Krasimir A. Spasov,Mariela Bollini,Karen S. Anderson,William L. Jorgensen +6 more
TL;DR: Catechol diethers that incorporate a 6-cyano-1-naphthyl substituent have been explored as non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) and promising compounds are reported that show midpicomolar activity against the wild-type virus and sub-20 nM activity against viral variants bearing Tyr181Cys and Lys103Asn mutations in HIV-RT.
36